Psoriasis Marketing
Agency in India.

Why psoriasis behaves nothing like acne.
The category's economic profile.

Psoriasis affects roughly 0.4 to 2.3 per cent of the Indian adult population — a range set by climate, latitude, and diagnostic access. The search volume is small compared to acne. First-consult conversion cycles are longer. The buyer is 25 to 60, comparing dermatologists on evidence and clinical infrastructure, not on price or Instagram aesthetic. And the patient, once diagnosed and stabilised, stays inside the practice for 5 to 10 years across biologic cycles, phototherapy courses, seasonal flare visits and topical refills.

The unit economics collapse to a single number: LTV. A well-retained psoriasis patient on biologic therapy contributes Rs.15,000 to Rs.40,000 of clinical margin per year, retained for 8 to 12 years, producing Rs.60,000 to Rs.1.8 lakh in lifetime relationship value. A psoriasis patient on phototherapy plus topicals contributes Rs.8,000 to Rs.22,000 annually over a 5-to-8-year relationship. Both economics dwarf the acquisition cost, which sits at a Rs.700 to Rs.1,800 CPQL. The marketing job is not to generate more first consults — it is to build the retention infrastructure that compounds LTV across the existing patient base and to nurture the search intent that the researching patient uses to decide where to establish care.

Biologics content — education, not brand comparison.
The NMC-safe framing.

The Indian psoriasis biologics landscape now includes secukinumab (IL-17A inhibitor), adalimumab and its biosimilars (TNF-alpha inhibitor), risankizumab (IL-23 inhibitor), and ustekinumab (IL-12/23 inhibitor). The category is expanding — patient awareness is expanding faster. A well-researched patient arrives at the consultation with 4 to 12 hours of prior reading and asks about specific molecules by name. The dermatologist who has published clear, evidence-based educational content on the biologic category compounds authority; the one who has not treats the same conversation from scratch every time.

The compliance frame that clears NMC Section 6 is molecule-education, not brand comparison. A page titled "Understanding IL-17 inhibitors for psoriasis" is compliant; a page titled "Cosentyx versus Taltz — which is better?" is not. The compliant framing is mechanism-of-action, indication, dosing schedule, monitoring requirements, and the trade-offs (efficacy versus safety versus cost) that a patient should discuss with their dermatologist. The compliant framing never names a specific brand as superior to another and never guarantees an individual patient's response.

The content stack that consistently earns organic ranking and citation on biologics queries: one hub page on biologics for psoriasis (mechanism categories, when biologics enter the treatment ladder, what to expect from the first six months), and a spoke page per molecule class (IL-17 inhibitors, TNF-alpha inhibitors, IL-23 inhibitors) with dosing schedules, monitoring requirements, cost-band ranges, and the CGHS/ECHS/PMJAY coverage picture as of the current year. Each page named-authored by a dermatologist with credentials, photograph and a linked biography.

The retention SOP.
Where the LTV actually gets captured.

A psoriasis patient captured but not retained is a Rs.700 to Rs.1,800 CPQL against a Rs.2,000 to Rs.4,500 first-consult and treatment cycle. A psoriasis patient captured and retained across 5 to 10 years is the same CPQL against Rs.60,000 to Rs.1.8 lakh in lifetime revenue. The 30 to 90 times LTV multiplier is entirely retention-driven. And retention infrastructure in psoriasis is a WhatsApp SOP layered on top of a clinical follow-up calendar, not a marketing campaign.

The SOP that consistently captures psoriasis LTV in our portfolio: (1) refill-window WhatsApp automation on the topical prescription cycle (day 22, day 55, day 85), (2) seasonal flare-management campaigns in winter (October to February) and post-monsoon (September) reminding patients to book a review before symptoms escalate, (3) an annual review nudge in November for patients who have not booked in six months, (4) a biologic-cycle reminder for patients on secukinumab or risankizumab tracking to the dosing schedule, (5) a teleconsult offer for out-of-station patients who established care during a family visit and now need a review.

The retention SOP execution rate is the operational metric that predicts psoriasis LTV compounding. Practices executing 85-plus per cent of the SOP touch-points on schedule retain 65 to 80 per cent of their psoriasis patient base into year three. Practices executing under 60 per cent retain 30 to 45 per cent. The infrastructure investment (a modest CRM + WhatsApp automation) pays for itself inside three quarters at any meaningful patient volume.

Answer Engine Optimisation
for chronic-condition queries.

Chronic-condition queries — "what causes psoriasis to flare," "is psoriasis autoimmune," "IL-17 inhibitors for psoriasis," "psoriasis versus eczema" — are heavily dominated by AI Overview citations and ChatGPT answers in 2026. The researching psoriasis patient is more likely to open ChatGPT than Google for the first three or four rounds of research; the practices that appear in these answers earn the trust anchor that Instagram cannot provide.

The AEO work for psoriasis: structure every biologics and phototherapy page for extraction (definition sentence, bulleted elaboration, longer discussion), mirror headings to the questions patients type ("What does secukinumab actually do for psoriasis?" outperforms "About secukinumab" as an H2), publish FAQPage schema on every hub and spoke, use named-author bylines with a linked biography page carrying credentials and prior publications. AI Overview weighting favours author authority for medical content more heavily than it does for other categories.